Table 3.
Comparison of Hospital Admissions Between Patients Treated With Casirivimab Plus Imdevimab or Bamlanivimab Stratified by Administration Early vs Late Administration Relative to Patient-Reported Symptom Onset
| ≥3 Days of Symptoms (n = 190) | <3 Days of Symptoms (n = 80) | Unadjusted OR (95% CI) | P Value | Adjusteda OR (95% CI) | P Value | |
|---|---|---|---|---|---|---|
| Casirivimab plus imdevimab | ||||||
| Admission for therapy-related failureb | 7 (3.7) | 6 (7.5) | 0.47 (0.15–1.45) | .190 | 0.69 (0.20–2.39) | .561 |
| Any admission | 14 (7.4) | 10 (12.5) | 0.56 (0.24–1.31) | .181 | 0.79 (0.30–2.10) | .625 |
| Bamlanivimab | ||||||
| Admission for therapy-related failureb | 17 (15.0) | 8 (11.4) | 1.37 (0.56–3.37) | .490 | 1.47 (0.57–3.81) | .424 |
| Any admission | 22 (19.5) | 10 (14.3) | 1.45 (0.64–3.28) | .371 | 1.55 (0.66–3.68) | .318 |
Abbreviations: mAb, monoclonal antibody; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Adjusted for age and comorbidity index.
Includes admission for both SARS-CoV-2 infection and adverse drug events within 30 days of mAb infusion.